# v4.25\n\n## Related releases\n\n## Data changes\n

### Gene

```
AKT1S1 Background Updated
AKT1S1 Summary Updated
ALOX15B Background Updated
ALOX15B Summary Updated
IKZF1 Background Updated
```

### Alteration

```
ACVR2A Truncating Mutations Name Changed
	 New: Truncating Mutations
	 Old: Truncating Mutation
AKT1S1 Amplification, Mutation Effect, Description Updated
AKT1S1 Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
AKT1S1 Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
AKT1S1 Amplification Added
ALOX15B Deletion, Mutation Effect, Description Updated
ALOX15B Deletion, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
ALOX15B Deletion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
ALOX15B Deletion Added
ALOX15B Truncating Mutations, Mutation Effect, Description Updated
ALOX15B Truncating Mutations, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
ALOX15B Truncating Mutations, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
ALOX15B Truncating Mutations Added
BRCA1 R504H, Mutation Effect, Description Updated
BRCA1 R504H, Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old:
BRCA1 R504H, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
BRCA1 R504H Added
BRCA2 C1290Y, Mutation Effect, Description Updated
BRCA2 C1290Y, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old:
BRCA2 C1290Y, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old:
BRCA2 C1290Y Promoted
BRCA2 R2341C, Mutation Effect, Description Updated
BRCA2 R2341C, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old:
BRCA2 R2341C, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old:
BRCA2 R2341C Added
EGFR L658Q, Mutation Effect, Description Updated
EGFR L658Q, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
EGFR L658Q, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
EGFR L658Q Added
EGFR S442I, Mutation Effect, Description Updated
EGFR S442I, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
EGFR S442I, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
EGFR S442I Added
EPCAM W143_A314trunc [3' Deletion] Deleted
FH G397R, Mutation Effect, Description Updated
FLT3 N676K, Mutation Effect, Description Updated
FLT3 N676S, Mutation Effect, Description Updated
FLT3 N676S, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old: Resistance
FLT3 N676D, Mutation Effect, Description Updated
FLT3 N676D, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old: Resistance
NRG1 ATP1B1-NRG1 Fusion Name Changed
	 New: ATP1B1-NRG1 Fusion
	 Old: ATP1B1-NRG1 fusion
STK11 G56W, Mutation Effect, Description Updated
```

### Evidence

```
AKT1S1 Gene Type, Oncogene Updated
ALK Fusions, Non-Small Cell Lung Cancer, Summary Updated
ALK Fusions, Non-Small Cell Lung Cancer, Ensartinib, Description Updated
ALK Fusions, Non-Small Cell Lung Cancer, Ensartinib, FDA Level Updated
	 New: Fda2
	 Old: no
ALK Fusions, Non-Small Cell Lung Cancer, Ensartinib, Level Updated
	 New: 1
	 Old:
ALK Fusions, Non-Small Cell Lung Cancer, Ensartinib, Propagation to Other Liquid Tumor Types Updated
ALK Fusions, Non-Small Cell Lung Cancer, Ensartinib, Propagation to Other Solid Tumor Types Updated
ALK Fusions, Non-Small Cell Lung Cancer, Ensartinib 1 Added
ALK Fusions, Other Tumor Types, Summary Updated
ALOX15B Gene Type, Tumor Suppressor Updated
ERBB2 Amplification, Breast Cancer, Trastuzumab Deruxtecan, Additional Information Updated
ERBB2 Amplification, Breast Cancer, Trastuzumab Deruxtecan, Description Updated
ERBB2 Oncogenic Mutations, Other Tumor Types, Summary Updated
ERBB2 Oncogenic Mutations, Cervical Cancer, Summary Updated
ERBB2 Oncogenic Mutations, Cervical Cancer, Neratinib, Description Updated
ERBB2 Oncogenic Mutations, Cervical Cancer, Neratinib, FDA Level Updated
	 New: Fda2
	 Old: no
ERBB2 Oncogenic Mutations, Cervical Cancer, Neratinib, Level Updated
	 New: 2
	 Old:
ERBB2 Oncogenic Mutations, Cervical Cancer, Neratinib, Propagation to Other Liquid Tumor Types Updated
ERBB2 Oncogenic Mutations, Cervical Cancer, Neratinib, Propagation to Other Solid Tumor Types Updated
ERBB2 Oncogenic Mutations, Cervical Cancer Added
ERBB2 Oncogenic Mutations, Cervical Cancer, Neratinib 2 Added
KRAS G12C, Colorectal Cancer, Summary Updated
KRAS G12C, Colorectal Cancer, Sotorasib + Panitumumab, Description Updated
KRAS G12C, Colorectal Cancer, Sotorasib + Panitumumab, FDA Level Updated
	 New: Fda2
	 Old: no
KRAS G12C, Colorectal Cancer, Sotorasib + Panitumumab, Level Updated
	 New: 1
	 Old:
KRAS G12C, Colorectal Cancer, Sotorasib + Panitumumab, Propagation to Other Liquid Tumor Types Updated
KRAS G12C, Colorectal Cancer, Sotorasib + Panitumumab, Propagation to Other Solid Tumor Types Updated
KRAS G12C, Colorectal Cancer, Sotorasib + Panitumumab 1 Added
KRAS G12C, Small Bowel Cancer, Summary Updated
KRAS G12C, Small Bowel Cancer, Adagrasib, FDA Level Updated
	 New: Fda2
	 Old: no
KRAS G12C, Small Bowel Cancer, Adagrasib, Level Updated
	 New: 2
	 Old:
KRAS G12C, Small Bowel Cancer, Adagrasib, Propagation to Other Liquid Tumor Types Updated
KRAS G12C, Small Bowel Cancer, Adagrasib, Propagation to Other Solid Tumor Types Updated
KRAS G12C, Small Bowel Cancer, Adagrasib, Description Updated
KRAS G12C, Small Bowel Cancer, Adagrasib 2 Added
KRAS G12C, Small Bowel Cancer, Sotorasib, Description Updated
KRAS G12C, Small Bowel Cancer, Sotorasib, FDA Level Updated
	 New: Fda2
	 Old: no
KRAS G12C, Small Bowel Cancer, Sotorasib, Level Updated
	 New: 2
	 Old:
KRAS G12C, Small Bowel Cancer, Sotorasib, Propagation to Other Liquid Tumor Types Updated
KRAS G12C, Small Bowel Cancer, Sotorasib, Propagation to Other Solid Tumor Types Updated
KRAS G12C, Small Bowel Cancer Added
KRAS G12C, Small Bowel Cancer, Sotorasib 2 Added
KRAS G12C, Colorectal Cancer, Adagrasib + Panitumumab, Sotorasib + Cetuximab Name Changed
	 New: 0a7b3eb1-d1f0-4511-aaac-9a696955bf57 + d7b1d12a-e942-4801-bb64-916c9bdfaaf3, 7d507726-ed2e-4f65-a35a-0e1e88984278 + 5fce3074-e420-4c36-9603-2423daf20118
	 Old: 0a7b3eb1-d1f0-4511-aaac-9a696955bf57 + d7b1d12a-e942-4801-bb64-916c9bdfaaf3, 7d507726-ed2e-4f65-a35a-0e1e88984278 + 5fce3074-e420-4c36-9603-2423daf20118, 7d507726-ed2e-4f65-a35a-0e1e88984278 + d7b1d12a-e942-4801-bb64-916c9bdfaaf3
KRAS G12C, Colorectal Cancer, Adagrasib + Panitumumab, Sotorasib + Cetuximab, Description Updated
KRAS G12C, Esophagogastric Cancer, Anal Cancer, Gastrointestinal Neuroendocrine Tumors of the Esophagus, Stomach, Tubular Adenoma of the Colon Name Changed
	 New: Esophagogastric Cancer, Anal Cancer, Gastrointestinal Neuroendocrine Tumors of the Esophagus/Stomach, Tubular Adenoma of the Colon
	 Old: Esophagogastric Cancer, Anal Cancer, Gastrointestinal Neuroendocrine Tumors of the Esophagus/Stomach, Small Bowel Cancer, Tubular Adenoma of the Colon
```
